New-onset persistent hyperglycemia with initiation of brentuximab treatment

Joseph Quintas, Kelley B. Mowatt, Jamie A. Mullally, Amir Steinberg

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The addition of brentuximab vedotin (BV) to adriamycin, vinblastine, and dacarbazine (AVD) has become the standard-of-care approach for advanced stage Hodgkin lymphoma (HL). This case describes a rare presentation of new-onset diabetes mellitus one month after initiation of BV + AVD therapy in a patient with HL. Case report: A 41-year-old woman with pre-diabetes and obesity was started on BV + AVD for classical HL, nodular sclerosing type. Six weeks after initiating therapy, she was admitted for abdominal pain, at which time her blood glucose was noted to be 357 mg/dL. Her Hba1c was 8.1%. She required rapid acting insulin, and throughout admission, her glucose ranged from 132 to 263 mg/dL. After discharge, a fasting glucose of over 250 mg/dL deemed her ineligible to have a PET/CT performed to assess disease status. Management and outcome: She was started on basal insulin, a DPP4-inhibitor, and a meglitinide analog. After initiation of therapy, her glucose levels were better controlled, and she was able to have her PET scan. Repeat Hba1c was 6.2% three months after initiation of glucose-lowering medications. She completed 6 cycles of BV + AVD therapy, with improving finger stick blood glucose (FSBG), and repeat Hba1c 1 month after completion of therapy was 5.2% on metformin monotherapy. Discussion: Reports of brentuximab-induced hyperglycemia are rare in the literature, noted in just a few studies and one case report. Our case demonstrates a need to monitor blood glucose levels carefully during the initiation of BV therapy, especially in individuals with risk factors such as obesity, pre-diabetes mellitus, or diabetes mellitus.

Original languageEnglish
JournalJournal of Oncology Pharmacy Practice
DOIs
StateAccepted/In press - 2023
Externally publishedYes

Keywords

  • Brentuximab
  • Hodgkin lymphoma
  • hyperglycemia
  • new onset
  • persistent

Fingerprint

Dive into the research topics of 'New-onset persistent hyperglycemia with initiation of brentuximab treatment'. Together they form a unique fingerprint.

Cite this